Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Calvert

Showing results (141-150 of 220) with videos related to

Pageof 22
Sort By:
Human Pathology|May 23, 2008
Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancerS J Wilkinson, A Kucukmetin, P Cross, et al.
Journal of Medicinal Chemistry|April 1, 1986
Quinazoline antifolates inhibiting thymidylate synthase: benzoyl ring modificationsT R Jones, M J Smithers, M A Taylor, et al.
Seminars in Oncology|December 1, 1996
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee studyD Porter, A Boddy, H Thomas, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1987
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatinD R Newell, Z H Siddik, L A Gumbrell, et al.
The Journal of Organic Chemistry|July 7, 2023
Traceless Thioacid-Mediated Radical Cyclization of 1,6-DienesDylan M Lynch, Mark D Nolan, Conor Williams, et al.
Seminars in Oncology|October 1, 1995
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactionsA H Calvert, A Boddy, N P Bailey, et al.
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1996
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parametersV Mummaneni, S Kaul, L N Igwemezie, et al.
Journal of Medicinal Chemistry|December 19, 1998
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)R J Griffin, S Srinivasan, K Bowman, et al.
British Journal of Cancer|January 1, 1997
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell linesE J Estlin, K Balmanno, A H Calvert, et al.
British Journal of Cancer|February 1, 1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277B J Foster, D R Newell, J Carmichael, et al.
Pageof 22

Showing results (141-150 of 220) with videos related to

Sort By:
Pageof 22
Human Pathology|May 23, 2008
Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancerS J Wilkinson, A Kucukmetin, P Cross, et al.
Journal of Medicinal Chemistry|April 1, 1986
Quinazoline antifolates inhibiting thymidylate synthase: benzoyl ring modificationsT R Jones, M J Smithers, M A Taylor, et al.
Seminars in Oncology|December 1, 1996
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee studyD Porter, A Boddy, H Thomas, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1987
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatinD R Newell, Z H Siddik, L A Gumbrell, et al.
The Journal of Organic Chemistry|July 7, 2023
Traceless Thioacid-Mediated Radical Cyclization of 1,6-DienesDylan M Lynch, Mark D Nolan, Conor Williams, et al.
Seminars in Oncology|October 1, 1995
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactionsA H Calvert, A Boddy, N P Bailey, et al.
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1996
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parametersV Mummaneni, S Kaul, L N Igwemezie, et al.
Journal of Medicinal Chemistry|December 19, 1998
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)R J Griffin, S Srinivasan, K Bowman, et al.
British Journal of Cancer|January 1, 1997
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell linesE J Estlin, K Balmanno, A H Calvert, et al.
British Journal of Cancer|February 1, 1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277B J Foster, D R Newell, J Carmichael, et al.
Pageof 22